Compare RF & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RF | INSM |
|---|---|---|
| Founded | 1970 | 1988 |
| Country | United States | United States |
| Employees | 19969 | 1664 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6B | 23.0B |
| IPO Year | N/A | 2000 |
| Metric | RF | INSM |
|---|---|---|
| Price | $27.88 | $106.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 24 |
| Target Price | $29.44 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 9.0M | 3.6M |
| Earning Date | 04-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.98 | $182.31 |
| Revenue Next Year | $3.82 | $65.19 |
| P/E Ratio | $13.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.79 | $65.56 |
| 52 Week High | $31.53 | $212.75 |
| Indicator | RF | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 33.71 |
| Support Level | $27.70 | $98.90 |
| Resistance Level | $28.06 | $166.81 |
| Average True Range (ATR) | 0.61 | 7.63 |
| MACD | 0.01 | -0.28 |
| Stochastic Oscillator | 69.79 | 18.01 |
Regions Financial is one of the midsized regional banks in the US, with around $160 billion in total assets as of the end of first quarter of 2026. Headquartered in Birmingham, Alabama, Regions Financial has a footprint mostly in the US Southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, wealth management, and capital markets.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.